Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 16/20 | 0.51 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.51 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | IGF1R | P08069 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4435210 | 0.90 | P2RY1 (0.53) | P2RY1P2RY14P2RY2NPC1RAB9A | |
| SCHEMBL4422591 | 0.89 | P2RY1 (0.57) | P2RY1P2RY14P2RY2NPC1RAB9A | |
| SCHEMBL4434000 | 0.84 | P2RY1 (0.53) | P2RY1P2RY14P2RY2NPC1RAB9A | |
| SCHEMBL4423200 | 0.84 | P2RY1 (0.53) | P2RY1P2RY14P2RY2NPC1RAB9A | |
| SCHEMBL1381324 | 0.80 | P2RY1 (0.54) | P2RY1P2RY14P2RY2KCNH2 | |
| SCHEMBL1380998 | 0.80 | P2RY1 (0.54) | P2RY1P2RY14P2RY2NPC1RAB9A | |
| SCHEMBL4423173 | 0.80 | P2RY1 (0.51) | P2RY1P2RY14P2RY2NPC1RAB9A | |
| SCHEMBL4552189 | 0.79 | P2RY1 (0.48) | P2RY1P2RY14P2RY2KCNH2 | |
| SCHEMBL4424620 | 0.78 | P2RY1 (0.52) | P2RY1P2RY14P2RY2NPC1RAB9A | |
| SCHEMBL4427908 | 0.78 | P2RY1 (0.53) | P2RY1P2RY14P2RY2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1984655-B | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB CO. (US) | 2011-11-30 | — | — | CN | claimed |
| EP-1750704-B1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB CO (US) | 2009-07-22 | — | — | EP | claimed |
| CN-1984655-A | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2007-06-20 | — | — | CN | claimed |
| US-20050261244-A1 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-24 | — | — | US | claimed |
| EP-1750704-B1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB CO (US) | 2009-07-22 | — | — | EP | disclosed |
| US-7550499-B2 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-23 | — | — | US | disclosed |
| US-20050261244-A1 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261244-A1 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | P2RY1, P2RY11, P2RY2 | P2RY1 1/4885P2RY14 14/4885P2RY2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.